Q1 2019 Virtual Emerging Medtech Spotlight

Event Online Now

Current Event

Welcome to Q1 2019 Emerging Medical Technologies Spotlight

Presenting Companies (Virtual)

Access from your Desktop on March 29, 2019 10am PT

AVVie

Implant for the treatment of mitral valve regurgitation

Jozef Tanczos

Jozef Tanczos

CSO

Olympus

We are seeking safe and efficient solutions that deliver minimally invasive treatment in the following fields:

-Flexible endoscopic procedures in the Gastrointestinal & Respiratory fields
-Laparoscopic surgery & Gynecological surgery in the General Surgery field
-Flexible or rigid endoscopic procedures in the Urology & Gynecology fields
-Flexible endoscopic procedures in the Ear, Nose and Throat field

Please contact us: medtech_innovation@Olympus.com
(Note) Any ideas, documents or information submitted in contacting us should be on a non-confidential basis. All ideas must have a patent filing.

Olympus -

Olympus -

Adan Medical Innovation

Our technology combines an app with a smartcase for autoinjectors to help patients manage their condition. Our first product, anAPPhylaxis, is for allergic individuals that have to carry at all times 2 epinephrine autoinjectors to prevent death in case of anaphylaxis, an extreme allergic reaction.

Xavier Guillem

Xavier Guillem

Ximedica

For more than 30 years Ximedica has provided a unique growth platform enabling organizations to successfully deploy medical technology products into the market. Ximedica was formed in 1985 by two Rhode Island School of Design (RISD) graduates, Aidan Petrie and Stephen Lane. From those earliest days to today, the application of "human-centered" design thinking to the innovation and product creation processes remains central to the company's success. In 2014 SV Life Sciences purchased a majority stake in the firm, recognizing that Ximedica is unique in providing a comprehensive service platform - a much needed option in the evolving ecosystem of outsourced medical device development. Throughout its history Ximedica has unearthed new opportunities for clients, solved difficult development challenges, delivered cutting edge innovative solutions and added considerably to patent counts. www.ximedica.com

Joe Gordon

Joe Gordon

Director of Innovation

AuriGen Medical

Left atrial appendage implant technology for the treatment of medication-resistant longstanding persistent atrial fibrillation
John Thompson

John Thompson

Co-founder

Cleveland Diagnostics

CDx is a development stage diagnostics company with a proprietary technology and ready to market high-performance, low-cost blood-based tests for early detection and diagnosis of cancer, when it can be treated and cured.

Arnon Chait

Arnon Chait

President & CEO

Impleo Medical

Company is developing a device therapy for Gastroesophageal Reflux Disease (GERD). The device is injected in the lower esophagus in a one-time procedure during GI endoscopy with no overnight hospital stay.

Juliana Elstad

Juliana Elstad

President & CEO

Medical Ingenuities

Radial artery occlusion device that achieves and confirms patent hemostasis
Richard - Chip Corrigan

Richard - Chip Corrigan

CEO

Suono Bio

Use of low frequency ultrasound to deliver unformulated therapeutics such as mRNA, siRNA, macromolecules directly into tissue. Initial focus on gastrointestional system and skin diseases.

Lisa Ricciardi

Lisa Ricciardi

CEO

SUTUREGARD Medical

Suture-based solutions for wound management

Daniel Ladizinsky

Daniel Ladizinsky

CEO

ThermopeutiX

The TwinFlo™ Catheter is designed to treat and protect the ischemic brain by providing rapid and selective cerebral hypothermia. It will offer a major advancement to the technology and treatment paradigms available to patients facing serious neurological damage and death. The unique design of TwinFlo™ results in more rapid and deeper localized cooling of the brain, while maintaining the remainder of the body at normal temperature (selective hypothermia). This differs from other hypothermia treatments that are unable to bring the brain to a sufficiently low temperature without significant total-body cooling and detrimental systemic effects. The design also permits selective drug and/or device delivery concurrent with the hypothermia treatment.

Ronald Solar

Ronald Solar

CEO

Access Includes

  • 10 minute streaming CEO Presentation for each company (audio and slides)
  • Downloadable Executive Summary (PDF) for each company
  • Stage of development, fundraising and strategic partnering overview for each company
  • Event notebook with Executive Summaries for all companies
  • Virtual networking/partnering tool to request additional information and meetings with companies
  • Ability to replay presentations post-event
Demo Profile Register Now

Trusted By The Companies Pioneering What’s Next